Multiple Myeloma Hub

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about cereblon E3 ligase modulators (CELMoDs) for the treatment of relapsed/refractory multiple myeloma (RRMM). During this interview, Richardson reviews clinical data on the activity of CELMoDs, including mezigdomide and iberdomide, in RRMM. Richardson highlights response rates observed in ongoing studies, including activity in heavily pretreated and B-cell maturation antigen (BCMA)-exposed patients, as well as in extramedullary disease. Richardson also discusses safety findings, including hematologic toxicity and infection risk, and outlines emerging data on combination strategies and ongoing phase III trials. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about the mechanism of action and immunomodulatory activity of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma. During this interview, Richardson discusses how CELMoDs target the cereblon E3 ubiquitin ligase complex to induce selective protein degradation and immunomodulatory effects. Richardson explains how CELMoDs, such as iberdomide and mezigdomide, differ structurally and functionally from earlier immunomodulatory drugs (IMiDs), resulting in enhanced substrate degradation and immune activation. He notes that anti-MM activity has also been demonstrated in combination with established myeloma therapies. Richardson also discusses translational and preclinical findings on the ability of CELMoDs to overcome resistance and modulate the tumor microenvironment.This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Hang Quach, St Vincent’s Hospital Melbourne and University of Melbourne, Melbourne, AU, delivered a presentation on optimizing dosing strategies for B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma (MM). In this presentation, Quach discusses the importance of dose modification in the real-world use of BCMA-directed therapies and emphasizes the need to balance efficacy and safety with long-term quality of life (QoL). Quach outlines dosing strategies for belantamab mafodotin and bispecific antibodies, and shares key clinical and patient-reported outcome data demonstrating the impact of dose adaptation on toxicity and QoL.This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity. 

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Fredrik Schjesvold, Oslo University Hospital, Oslo, NO, provided an overview of B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma (MM). During this presentation, Schjesvold provides an overview of currently available BCMA-directed therapies, including antibody–drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Schjesvold outlines differences in mechanisms of action, regulatory approvals, treatment settings, and key efficacy and safety data across approved agents. This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Rakesh Popat, University College Hospital, London, UK, delivered a presentation on quality-of-life (QoL) considerations with B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma (MM).  In this presentation, Popat discusses the importance of health-related QoL as a key clinical outcome in MM, particularly in the context of increasingly effective therapies. Popat emphasizes the need to balance efficacy and safety with QoL and outlines patient-, disease-, and treatment-related factors that influence QoL. Practical considerations, including treatment logistics, adverse events, and patient preferences, are also discussed, alongside approaches to assessing QoL and incorporating shared decision-making into clinical practice. This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity. 

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. During the symposium, the panel, chaired by Hermann Einsele, discussed the practical considerations when sequencing novel agents and managing adverse events with B-cell maturation antigen (BCMA)-directed therapies in relapsed/refractory multiple myeloma (RRMM). The session covered mechanisms of resistance with BCMA-targeted therapies; the impact of prior exposure to BCMA-directed therapies; the main differences between BCMA-directed antibody–drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies in terms of access, logistics, and toxicity profiles; and how dosing schedules can be adapted to optimize efficacy while limiting toxicity. This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Maria Victoria Mateos provided an overview of the potential future directions with novel and established B-cell maturation antigen (BCMA)-directed therapies in the multiple myeloma (MM) treatment paradigm. This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Gordon Cook, University of Leeds, UK, delivered a presentation covering real-world insights and clinical experience with BCMA-directed therapies.In this presentation, Cook examined how populations enrolled in pivotal trials of BCMA-directed therapies compare with patients treated in routine clinical practice. Key differences were highlighted, including age, performance status, comorbidities, and prior treatment exposure. Cook presented data for bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies, focusing on efficacy and safety outcomes in real-world populations as well as the impact of prior BCMA exposure on response and durability of response. Real-world experience with adverse events, particularly infections and ocular complications, was also discussed, as were the implications of these findings for treatment sequencing as BCMA-directed therapies move into earlier lines of therapy.This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.